Get the Stockscreener App
2.01
4.69%
0.09
After Hours:
2.04
0.03
+1.49%
Prokidney Corp stock is traded at $2.01, with a volume of 1.22M.
It is up +4.69% in the last 24 hours and up +23.31% over the past month.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$1.92
Open:
$1.9
24h Volume:
1.22M
Relative Volume:
1.03
Market Cap:
$419.94M
Revenue:
$889.00K
Net Income/Loss:
$-156.28M
P/E Ratio:
-3.8162
EPS:
-0.5267
Net Cash Flow:
$-150.06M
1W Performance:
+9.84%
1M Performance:
+23.31%
6M Performance:
-18.29%
1Y Performance:
-12.61%
1-Day Range:
$1.89
$2.09
1-Week Range:
$1.7807
$2.09
52-Week Range:
$1.30
$3.4799
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
2.01 | 296.68M | 889.00K | -156.28M | -150.06M | -0.5267 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | H.C. Wainwright | Buy |
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
ProKidney (NASDAQ:PROK) Stock Price Up 7.6%Should You Buy? - MarketBeat
ProKidney Corp (PROK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
3 Promising Penny Stocks With Market Caps Larger Than $200M - simplywall.st
Keep An Eye On ProKidney As Insider Stock Selling Hits US$3.0m - 富途牛牛
ProKidney (PROK) EPS and Revenue: Headline Results Are Close to Consensus; Post-Earnings: The Stock Closes Near UnchangedBanking Earnings Report - vinanet.vn
ProKidney director Brian Pereira sells $1.07 million in shares By Investing.com - Investing.com Canada
ProKidney director Brian Pereira sells $1.07 million in shares - Investing.com
ProKidney (PROK) Quarter in Focus: The Available Figures Are Largely in Line; Post-Report: Shares Fall 4.05% in the Latest ReadingGuidance Update - vinanet.vn
Brian Jg Pereira Sells 229,338 Shares of ProKidney (NASDAQ:PROK) Stock - MarketBeat
ProKidney (NASDAQ:PROK) Director Sells 222,949 Shares - MarketBeat
Prokidney Insider Sold Shares Worth $1,067,773, According to a Recent SEC Filing - marketscreener.com
ProKidney Director Sold Shares Worth Over $1.0M - TradingView
ProKidney (PROK) director sells 757K shares over 3 days - Stock Titan
ProKidney (PROK) Close: Ends Higher by 3.99% at $1.44 at the Close; Immediate View: Support at $1.37 and Resistance at $1.51 Frame the Range under the Current SnapshotHigh Beta Stocks - dars.gov.et
ProKidney (NASDAQ: PROK) director plans new restricted stock sale - Stock Titan
ProKidney (NASDAQ: PROK) director plans sale after trust offloads 229K - Stock Titan
ProKidney (PROK) Latest Reading: Moves 0.71% Lower to $1.39 in the Current Update; Range Context: the Near-Term Reference Band Stretches From $1.32 to $1.46 in Latest TradingFibonacci Entry Signals - vinanet.vn
ProKidney (PROK) Earnings Comparison: Results Show Limited Variance From Forecasts in the Latest Session; Market Follow-Through: The Market Price Declines 0.36% on the DayPost-Earnings Reaction - vinanet.vn
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) (PROK) - Seeking Alpha
PROK Q1 2026 Earnings: Narrow EPS Beat Overshadowed by 5% Stock DeclineEarnings Volatility Report - vinanet.vn
What is HC Wainwright's Estimate for ProKidney Q3 Earnings? - MarketBeat
ProKidney Corp. (PROK) Slides 9.3% to $1.46 as Key Support Level Comes into FocusVolume Breakout Ideas - dars.gov.et
Morgan Stanley (PROK) filings show ProKidney stake at 4.7% and below 5% level - Stock Titan
ProKidney (PROK) Gets a Buy from Guggenheim - The Globe and Mail
ProKidney FY2030 EPS Estimate Decreased by HC Wainwright - MarketBeat
ProKidney reports larger second-quarter loss as key clinical trial expenses mount - Winston-Salem Journal
ProKidney earnings missed, revenue topped estimates By Investing.com - Investing.com Nigeria
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
ProKidney earnings missed, revenue topped estimates - Investing.com
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
ProKidney completes Phase 3 PROACT 1 accelerated approval enrollment - scanx.trade
ProKidney (NASDAQ:PROK) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
ProKidney reports Q2 revenue of $150,000 as PROACT 1 advances - Quiver Quantitative
Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise - TradingView
PROK: Completed key Phase 3 trial enrollment; cash supports operations into mid-2027 - TradingView
ProKidney Corp. (NASDAQ: PROK) warns on cash runway after $89M H1 loss - Stock Titan
ProKidney Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProKidney Announces Q2 2026 Financial Results Highlighting Increased Losses and R&D Spending - Kalkine Media
ProKidney Corp (PROK) Stock News Today - TradingKey
PROK Q1 2026 Earnings: Slight EPS Beat Signals Discipline as Clinical Pipeline Drives ValueOne-Time Gain Impact - vinanet.vn
ProKidney Corp. (PROK) director converts paired units into Class A stock - Stock Titan
3 Promising Penny Stocks With Market Caps Under $500M - simplywall.st
PROK Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
ProKidney (PROK) to Release Quarterly Earnings on Tuesday - marketbeat.com
ProKidney Corp. Revenue Breakdown – NASDAQ:PROK - TradingView
ProKidney Corp (PROK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ProKidney (PROK) Climbs 2.6% to $1.58 as Renal Biotech Tests Key Technical LevelsTriple Bottom - vinanet.vn
ProKidney Corp (PROK) Income Statement - TradingKey
ProKidney Corp (PROK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PROK|ProKidney Corp|Price:1.565|Chg%:+0.025 - TradingKey
ProKidney Corp (PROK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prokidney Corp Stock (PROK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pereira Brian JG | Director |
Aug 20 '26 |
Sale |
1.42 |
222,948 |
316,564 |
0 |
| Pereira Brian JG | Director |
Aug 18 '26 |
Sale |
1.37 |
229,338 |
314,468 |
445,897 |
| Pereira Brian JG | Director |
Aug 19 '26 |
Sale |
1.44 |
27,051 |
38,972 |
27,052 |
| Pereira Brian JG | Director |
Aug 20 '26 |
Sale |
1.42 |
27,052 |
38,411 |
0 |
| Pereira Brian JG | Director |
Aug 18 '26 |
Sale |
1.37 |
27,826 |
38,155 |
54,103 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):